The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER
Jianing Tang,1 Deguang Kong,2 Qiuxia Cui,1 Kun Wang,3 Dan Zhang,3 Xing Liao,1 Yan Gong,4 Gaosong Wu1 1Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China; 2Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China; 3Department of Br...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-06-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/the-role-of-radioactive-iodine-therapy-in-papillary-thyroid-cancer-an--peer-reviewed-article-OTT |
id |
doaj-15b9637052d340b390d1aba8371725b0 |
---|---|
record_format |
Article |
spelling |
doaj-15b9637052d340b390d1aba8371725b02020-11-24T21:39:01ZengDove Medical PressOncoTargets and Therapy1178-69302018-06-01Volume 113551356038894The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEERTang JKong DCui QWang KZhang DLiao XGong YWu GJianing Tang,1 Deguang Kong,2 Qiuxia Cui,1 Kun Wang,3 Dan Zhang,3 Xing Liao,1 Yan Gong,4 Gaosong Wu1 1Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China; 2Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China; 3Department of Breast and Thyroid Surgery, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 4Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, China Background: Papillary thyroid cancer (PTC) is a common endocrine malignancy with relatively good prognosis. Radioactive iodine (RAI) is considered effective for patients with total or nearly total thyroidectomy, but the beneficial effects of RAI are still controversial. Materials and methods: To determine whether RAI therapy could improve the survival rates of PTC patients, we conducted a retrospective analysis using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. Disease-specific survival (DSS) was obtained using multivariate Cox proportional hazard regressions. Results: DSS was improved by RAI ablation in patients with tumor >2 cm, age >45 years and gross extrathyroidal or lymph node metastasis. In a further analysis, RAI therapy did not improve the DSS in patients with tumor <2 cm except those with distant metastasis. For patients with tumor >2 cm, those involving gross extrathyroidal extension, age >45 years or disease in the lymph nodes, DSS was improved after RAI therapy. Patients with distant metastasis always benefited from RAI ablation. Conclusion: RAI ablation should be recommended to patients with tumor <2 cm and distant metastasis or patients with tumor >2 cm and one of the following risk factors: gross extrathyroidal extension, age >45 years, lymph node and distant metastases. Keywords: RAI, prognosis, tumor size, metastasis, extension, agehttps://www.dovepress.com/the-role-of-radioactive-iodine-therapy-in-papillary-thyroid-cancer-an--peer-reviewed-article-OTTPapillary thyroid cancerSEERradioactive iodine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tang J Kong D Cui Q Wang K Zhang D Liao X Gong Y Wu G |
spellingShingle |
Tang J Kong D Cui Q Wang K Zhang D Liao X Gong Y Wu G The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER OncoTargets and Therapy Papillary thyroid cancer SEER radioactive iodine |
author_facet |
Tang J Kong D Cui Q Wang K Zhang D Liao X Gong Y Wu G |
author_sort |
Tang J |
title |
The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER |
title_short |
The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER |
title_full |
The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER |
title_fullStr |
The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER |
title_full_unstemmed |
The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER |
title_sort |
role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on seer |
publisher |
Dove Medical Press |
series |
OncoTargets and Therapy |
issn |
1178-6930 |
publishDate |
2018-06-01 |
description |
Jianing Tang,1 Deguang Kong,2 Qiuxia Cui,1 Kun Wang,3 Dan Zhang,3 Xing Liao,1 Yan Gong,4 Gaosong Wu1 1Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China; 2Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China; 3Department of Breast and Thyroid Surgery, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 4Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, China Background: Papillary thyroid cancer (PTC) is a common endocrine malignancy with relatively good prognosis. Radioactive iodine (RAI) is considered effective for patients with total or nearly total thyroidectomy, but the beneficial effects of RAI are still controversial. Materials and methods: To determine whether RAI therapy could improve the survival rates of PTC patients, we conducted a retrospective analysis using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. Disease-specific survival (DSS) was obtained using multivariate Cox proportional hazard regressions. Results: DSS was improved by RAI ablation in patients with tumor >2 cm, age >45 years and gross extrathyroidal or lymph node metastasis. In a further analysis, RAI therapy did not improve the DSS in patients with tumor <2 cm except those with distant metastasis. For patients with tumor >2 cm, those involving gross extrathyroidal extension, age >45 years or disease in the lymph nodes, DSS was improved after RAI therapy. Patients with distant metastasis always benefited from RAI ablation. Conclusion: RAI ablation should be recommended to patients with tumor <2 cm and distant metastasis or patients with tumor >2 cm and one of the following risk factors: gross extrathyroidal extension, age >45 years, lymph node and distant metastases. Keywords: RAI, prognosis, tumor size, metastasis, extension, age |
topic |
Papillary thyroid cancer SEER radioactive iodine |
url |
https://www.dovepress.com/the-role-of-radioactive-iodine-therapy-in-papillary-thyroid-cancer-an--peer-reviewed-article-OTT |
work_keys_str_mv |
AT tangj theroleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT kongd theroleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT cuiq theroleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT wangk theroleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT zhangd theroleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT liaox theroleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT gongy theroleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT wug theroleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT tangj roleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT kongd roleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT cuiq roleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT wangk roleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT zhangd roleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT liaox roleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT gongy roleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer AT wug roleofradioactiveiodinetherapyinpapillarythyroidcanceranobservationalstudybasedonseer |
_version_ |
1725933132713033728 |